Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients

Lucas M. Bryant, MD; Kelly E. Daniels, BS; David M. Cognetti, MD; Patrick Tassone, MD; Adam J. Luginbuhl, MD; Joseph M. Curry, MD

Objectives: 1) review benefits and risks of cannabis use, with emphasis on otolaryngic disease processes; 2) define and review the endocannabinoid signaling system (ESS); and 3) review state and federal regulations for the use and research of cannabis and ESS modulators.

Methods: This manuscript is a review of the current literature relevant to the stated objectives.

Results: Cannabis (marijuana) use is increasing. It is the most widely used illicit substance in the world. There is increasing interest in its therapeutic potential due to changing perceptions, new research, and legislation changes controlling its use. The legal classification of cannabis is complicated due to varied and conflicting state and federal laws. There are currently two synthetic cannabinoid drugs that are FDA approved. Current indications for use include chemotherapy-related nausea and vomiting, cachexia, and appetite loss. Research has demonstrated potential benefit for use in many other pathologies including pain, inflammatory states, and malignancy. Data exists demonstrating potential antineoplastic benefit in oral, thyroid, and skin cancers.

Conclusions: ESS modulators may play both a causal and therapeutic role in several disorders seen in otolaryngology patients. The use of cannabis and cannabinoids is not without risk. There is a need for further research to better understand both the adverse and therapeutic effects of cannabis use. With increasing rates of consumption, elevated public awareness, and rapidly changing legislation, it is helpful for the otolaryngologist to be aware of both the adverse manifestations of use and the potential therapeutic benefits when talking with patients.

INTRODUCTION

The purpose of this review is to provide the practicing otolaryngologist with a foundational knowledge of current therapeutic uses of cannabinoids and effectors of the endocannabinoid signaling system (ECS). It includes a brief overview of the biochemical principles guiding the physiologic effects of the ECS, addresses the risks and adverse effects of cannabis use, and finally reviews current state and federal legislation.

Cannabis (marijuana) use is increasing and is currently the most widely used illicit substance both worldwide and within the United States. Cannabis has been used for centuries as a treatment for myriad medical ailments. It has shown potential to be of therapeutic use in several pathologies including nausea, pain, weight/apetite loss, inflammation, anxiety, multiple sclerosis-related muscle spasticity, neuropathy, seizure, and even cancer. There has been a recent resurgence of interest in its therapeutic potential, which is likely due to a combination of changing societal perceptions, new scientific discoveries, and recent legislation measures relating to its regulation. The legal classification of cannabis is complicated due to conflicting legislation of the state and federal governments. At present, the federal government still classifies marijuana as a schedule I controlled substance and does not approve it for any medical uses. At the state level, 29 states and the District of Columbia have legalized comprehensive medical marijuana and cannabis programs, while an additional 17 states have highly regulated medical marijuana programs legalizing its use in more limited medical situations. This means that for patients in a majority of states, medical marijuana is increasingly becoming an accessible and entirely novel option for management of their ailments. The current increase in use for medical purposes appears to be commensurate with recent changes in state and federal legislative policies as well as international studies demonstrating a biochemical basis for the therapeutic effects seen with cannabis use. As the use of marijuana and other complementary medicine therapies continues to rise, patients may expect their physicians to explain both the potential merits and harms they may experience with its use.

Unlike many other biocutreal therapies which may be used by the otolaryngology patient, marijuana poses additional challenges due to its current federal classification as a schedule I substance. As scientific evidence of
its therapeutic benefit advances, it is vital that physicians are well informed in order to confidently provide sound guidance when questioned by patients. Additionally, the physician must be kept abreast of the current regulatory status in order to ensure they keep their practice within the rapidly changing legal boundaries of both state and federal legislation.

CANNABIS CLASSIFICATION AND BIOLOGY

Marijuana is derived from plants in the Cannabis family. There are two main species: Cannabis sativa and Cannabis indica. Hemp is a nonpsychoactive cannabis plant product that is used in beauty creams, rope, clothing and other domestic goods. There are hundreds of marijuana “chemotypes” derived from the foundational sativa and indica strains. Each strain is designed with a goal of modulating the relative concentrations of certain biologically active molecules, called phytocannabinoids. Customized variations in phytocannabinoid levels subsequently provide the user with a customized sensory experience (in the case of recreational use) or therapeutic effect (medicinal use).

Although there are many biologically active phytocannabinoids in cannabis, two predominate in the current literature. In 1964, Gaoni and Mechoulam described the psychoactive cannabinoids found in Cannabis sativa: Δ⁸-tetrahydrocannabinol (Δ⁸-THC) and Δ⁹-tetrahydrocannabinol (Δ⁹-THC). Δ⁹-THC is more potent and found in higher concentrations within the plant. It is the primary cannabinoid referred to when “THC” is referenced in this paper. THC is metabolized within the lungs and liver into 11-hydroxy-Δ⁹-THC which is active within the CNS and elsewhere. Jean-Baptiste Lamarck described Cannabis indica as a second strain of cannabis in 1785. Cannabis indica is clinically distinct from Cannabis sativa due to the higher relative concentration of cannabidiol (CBD), another phytocannabinoid.

THC is most commonly associated with the euphoric feelings users experience due to its psychoactive effects. In addition to a sense of euphoria, it also appears to possess anti-emiatic, anti-inflammatory, analgesic, and antioxidant properties. In contrast to THC, CBD has traditionally been viewed as a nonpsychoactive cannabinoid. CBD is credited for offering users analgesic, antiinflammatory, anxiolytic, antipsychotic, and sedative effects. The anxiolytic and antipsychotic effects have been purported to participate in decreasing these adverse effects seen with THC use. This observation is one reason some proponents argue for extracts instead of synthetic cannabinoids which could ultimately cause more adverse effects through loss of this natural synergistic relationship between phytocannabinoids. When derived from hemp, and absent of THC, CBD containing products are not under federal regulation.

METHODS OF CONSUMPTION

There are several methods commonly used in cannabis consumption. The most traditional method of cannabis consumption is unfiltered smoking. This results in the user inhaling the combustion products in cannabis smoke. Smoking cannabis allows for rapid onset of effects (2–10 minutes), short duration of action, and ease of titratability. It is important to note that smoking is the primary delivery method used in nearly all studies assessing the risks of cannabis use. Cannabis is typically smoked in an unfiltered manner and the smoke itself may reach temperatures as high as 700°C. The combustion process results in partial breakdown of cannabinoids with simultaneous production of undesirable carcinogens. Marijuana smoke has a similar carcinogen profile as tobacco smoke, but may have higher relative concentrations of certain carcinogens.

Another method of cannabis use is enteral consumption. Although this method avoids the carcinogen exposure of smoked cannabis, it has several downfalls. The onset of action and maximum effect is significantly more delayed (1–6 hrs) than smoking, therapeutic effects are less easily titratable secondary to inconsistent bioavailability (6–20%), and the duration of action is prolonged (20–30 hours). Recently, vaporization has gained popularity as a method of cannabis consumption. Vaporization is a process by which a material is heated to temperatures that allow for vaporization of phytocannabinoids (170–300°C). Vaporization retains the desirable pharmacokinetic profile of smoked marijuana while preventing the creation of harmful carcinogens by avoiding combustion. Although vaporization appears to be a promising delivery method, it is not well studied and vaporization units are not FDA regulated, subjecting users to potential untoward exposure to heat mediated degradation products of plastics or heavy metals within the vaporizer unit.

ENCANNABINOID SIGNALING SYSTEM

The endocannabinoid signaling system (ESS) is complex and promiscuous. In vivo, it acts as a short-range, short-term response system to acute physiologic events. The ESS can be thought of as an “on demand” system, where endocannabinoids are synthesized locally in response to acute local stimuli. It is composed of ligands (cannabinoids), cell surface receptors, and several intracellular signaling pathways that induce enzymatic reactions. These enzymatic reactions may either agonize or attenuate cellular function. Stimulation of the ESS can induce myriad effects, which are discussed elsewhere in this paper. Ligands of the ESS can be autogenous molecules (endocannabinoids), plant derivatives (phytocannabinoids), or synthetic cannabinoids. Phytocannabinoids, synthetic cannabinoids, and ESS modulating drugs exert their effects within the body through manipulation of normal ESS physiology.

Endocannabinoids are biologic molecules made within the body that act on known cannabinoid receptors. In 1992, the first endocannabinoid, anandamide (AEA), was described. Since then, several other arachidonic acid-derived endocannabinoids have been described, including 2-arachidonoylglyceryl ether (2-AG), O-arachidonyl-ethanolamine (virodhamine), and N-arachidonoyl dopamine (NADA). In general, endocannabinoids act in a paracrine fashion by binding to appropriate cell surface receptors that express appropriate cannabinoid-sensitive receptors.
receptors.27–29 After internalization, endocannabinoids are metabolized by various degradatory enzymes including FAAH, DAGL, and MAGL (fatty acid amine hydrolase, diacyl glycerol lipase, monoacyl glycerol lipase) (Table I).30,31

| Select Endocannabinoids by Common and Chemical Name. | \( N \)-arachidonoyl-ethanolamine |
|---------------------------------------------|----------------------------------|
| Anandamide/AEA | N-arachidonoyl-dopamine |
| 2-AG | 2-arachidonoyl glycerol |
| Noladin ether | 2-arachidonoyl glyceryl ether |
| Virodhamine | O-arachidonoyl-ethanolamine |

There are two primary cannabinoid receptors that have been well described. They were sequentially named cannabinoid receptor 1 and 2 (CB1, CB2) based on timing of discovery. CB1 was discovered and described in the late 1980s and early 1990s using a rat model. CB2 was subsequently described in 1993 in a study using human cell cultures.26,32,33 Both CB1 and CB2 are G-protein coupled receptors (GPCRs), and each of them has been shown to function in unique physiologic pathways, in part due to their distinct sites of expression.34–38 Apart from CB1 and CB2, transient receptor potential vanilloid type 1 (TRPV1), a lipid responsive ion channel, has also demonstrated some cannabinoid binding affinity.39 Of note, CBD has a relatively weak affinity for both CB1 and CB2, which may explain the apparent antagonistic effect it has been reported to have when used with other CB receptor agonists.25,40

CB1 is predominantly found within the brain and other central nervous system structures but is also expressed in other locations including the spleen, eye, and reproductive organs (Fig. 1). Upon receptor activation, CB1 acts through a variety of intracellular mechanisms. It inhibits adenylate cyclase, resulting in decreased levels of cyclic adenosine monophosphate (cAMP). CB1 also activates mitogen-activated protein kinase (MAPK), extracellular signal-related kinase (ERK), and phosphatidylinositol-3 kinase (PI3K) signaling pathways, among others.6,19,34,41,42 CB1 is able to couple with any class of receptor-activated G-proteins, including \( G_s, G_i, \) and \( G_q \), each of which initiates its own set of unique signaling mechanisms. CB1’s diversity in effector mechanisms is further broadened by the receptor’s ability to form heterodimers with other receptors. The distinct combination of g-protein pairing and heterodimerization of any one CB1 receptor creates a nuanced signaling pathways.45,46 Unlike CB1, which may promote a proinflammatory response, CB2 signaling appears to decrease reactive oxygen species (ROS).47

**OTOLARYNGIC AND GENERAL MANIFESTATIONS OF CANNABIS USE**

As with other aspects of marijuana, there is conflicting data regarding the risks associated with cannabis and cannabinoid use. In general, adverse effects can be separated into those seen with acute or chronic use, and those seen with extremely high (intoxication) doses. These effects are summarized in Tables II and III. Most purported adverse effects of marijuana use appear to present in a dose-dependent manner, regardless of age.48

Acute physiologic effects of cannabis use include tachycardia, bronchodilation, conjunctival irritation, and decreased intraocular pressure.49 Although previous data appears to support marijuana use having a negative effect on neural development when used in young people, a recent prospective study conducted in the UK demonstrated this tendency might be negated in moderate users when other factors such as tobacco and alcohol use are accounted for.50,50–52 There is data supporting a correlation with mental illness, including schizophrenia, and heavy use.50 The association between marijuana use and mental illness has not been shown to be causative. Marijuana may induce earlier or stronger psychotic events in individuals with a preexisting disposition toward mental illness.5

Driving impairment remains a concern in patients under the influence of marijuana. In contrast to alcohol
intoxication, cannabis intoxication levels and risk of driving impairment are not as predictable due to wider levels of tolerance between users.\(^{53}\) Cannabis intoxication does not appear to impair drivers to the same extent as alcohol, but has been shown to function synergistically when individuals are intoxicated by both.\(^{53,64}\) This association with increased motor vehicle accidents extends to other sources of trauma as well. Gerberich et al. found that cannabis use to increase hospital admission rates for all causes of injury.\(^{55}\)

Chronic effects of marijuana use include respiratory tract inflammation (primarily if smoked), dependence, depressive symptoms, and failure to achieve academically and professionally. Although less addictive than many other illicit substances, marijuana does carry a risk of dependence, with approximately 1 in 10 users demonstrating some level of dependence.\(^{3,48,56}\) Marijuana does not appear to increase the rate of birth defects when used during pregnancy, but may be associated with decreased birth weight, preterm labor, and increased rate of admission to a neonatal intensive care unit after birth.\(^{57}\) Finally, although the mortality risk of marijuana use remains unclear, it has also been associated with an increased risk of cardiac events and stroke.\(^{48,58,59}\)

Despite the apparently similar carcinogenic profile between marijuana and tobacco smoke, current data does not clearly support marijuana smoking as a clear risk factor for lung cancer.\(^{60-64}\) Studies assessing marijuana use and risk of head and neck cancers are also mixed and data is weakened by confounding factors (namely tobacco), low power, and exposure to recall bias due to their retrospective nature.\(^{61,62,64-67}\) Some data shows marijuana use to be potentially protective against tongue cancers (OR 0.47, 95% CI 0.29–0.75) and other oropharyngeal cancers, while concomitantly serving as an independent risk factor for human papilloma virus (HPV)–positive oral tumors.\(^{68,69}\) Gillison et al. reported the possibility that the increased risk of HPV positive cancers seen in marijuana smokers may be due to certain immunomodulatory effects of cannabis. By inducing a shift from Th\(_1\) to Th\(_2\) immune responses, cannabinoids may decrease resistance to intracellular bacterial and viral infection. Once infected, the host would also suffer from attenuation of normal physiologic clearing of viral infection. This would ultimately result in more virulent HPV infections and increased rates of HPV-positive cancer.\(^{68}\) There are no clinical studies assessing cancer risk in users via oral ingestion or vaporization.

Although a correlation between cannabis smoking and lung cancer is non-definitive, there is data that demonstrates cannabis smoke as a mucosal irritant and source of oxidative stress to respiratory epithelium.\(^{70}\) There are also reports of increased incidence of fungal sinusitis; possibly due to \textit{Aspergillus} contaminant of the smoked plant.\(^{71,72}\) Although rare, allergic reactions to marijuana have also been reported. These reactions range from type I hypersensitivity (rhinoconjunctivitis) to anaphylaxis.\(^{73}\) There is also evidence that marijuana users experience increased rates of periodontal disease and dental carries.\(^{74}\) Data also correlates marijuana smoking with respiratory mucosa inflammation, stomatitis, ululitis, cough, and increased sputum production.\(^{19,75}\) Fortunately, these acute respiratory inflammatory responses to smoked marijuana tend to subside soon after cessation of smoking.\(^{76}\)

**CURRENT CANNABINOID-BASED THERAPIES**

At the time of this writing, there are no FDA approved uses for cannabis. There are currently two

---

### TABLE II. Overview of Adverse Effects of Cannabis Use.

| Acute\(^{48}\) | Chronic | Intoxication |
|---|---|---|
| Tachycardia, bronchodilation, conjunctival irritation, decreased intraocular pressure\(^{38}\) | Dependence | Anxiety |
| Impaired judgment | Respiratory tract inflammation (smoked) | Psychosis, paranoia, mania |
| Impaired short-term memory | Correlation with mental illness incl. depression & schizophrenia* | Hallucinations |
| Increased appetite | Cognitive impairment | |
| Driving impairment | Depression | |
| Paranoia | | |

*Especially in patients with preexisting predisposition to mental illness.

---

### TABLE III. ENT-Specific Adverse and Therapeutic Effects Associated With Cannabinoid Use.*

| Associated Increased Risk | Associated Decreased Risk |
|---|---|
| Allergic reaction (type I hypersensitivity) | Tongue cancer |
| HPV-related oropharyngeal cancer | Other oropharyngeal cancers |
| Cough, increased sputum production | Decreased intraocular pressure |
| Fungal sinusitis (Aspergillus) | Potential antineoplastic effects in skin cancer (melanoma, basal cell, squamous cell) |
| Inflammation of respiratory mucosa (rhinitis, stomatitis, ululitis, pharyngitis, bronchitis) | Potential antineoplastic effects in thyroid cancer (anaplastic) |
| Peridontal disease, dental caries | |
| Stomatitis, xerostomia | |

*Most data of adverse effects relates to smoked marijuana use and may not apply for other delivery methods.
synthetic THC formulations available within the United States, dronabinol (Marinol) and nabilone (Cesamet). Dronabinol is a schedule III cannabinoid and nabilone is a schedule II cannabinoid. Nabiximols (Sativex) is a liquid cannabis extract composed of THC and CBD. It is used as an oral spray and is approved for use in several European countries, but not currently within the United States. Indications for both dronabinol and nabilone include the treatment of recalcitrant nausea and vomiting following chemotherapy in cancer patients. Dronabinol is also approved as an appetite stimulant in diseases such as AIDS which result in severe weight loss.77–84 (Table IV)

**POTENTIAL THERAPIES FOR THE OTOLARYNGIC PATIENT**

In addition to current FDA recognized indications for use of synthetic cannabinoids, there is growing evidence of therapeutic potential of both biocutical and synthetic cannabinoids. Three of the most interesting potential uses are for the management of pain, various inflammatory disorders, and cancer.

**Pain**

Recently, cannabis has gained attention for use as a therapy modality for chronic pain patients, including those with inflammatory, neuropathic, and cancer-related pain.8,77,84,83,85–93 Compared to other pain regimens, cannabinoid-based therapies appear to maintain a desirable safety profile when used for chronic pain management. Most adverse effects are mild (dizziness, xerostomia, nausea, and fatigue).86 Cannabis typically has a moderate analgesic effect, and may function best when used synergistically with opioids for pain control.93 Paudel showed CBD delivery for chronic, extended use could be done via transdermal methods, whereas CBD use for breakthrough pain could be achieved using an intranasal method, allowing for a more rapid onset of approximately 10 minutes.87 The mortality and morbidity associated with narcotic use for pain control continues to be a serious concern for physicians. In 2014, Bachhuber et al. reported a nearly 25% decrease in opioid-related mortality in states which have enacted a medical marijuana program.94 Future advances in harnessing the ESS for pain treatment may focus on the development of CB2 preferential agonists.85

**Inflammation**

The endocannabinoid signaling system plays an active role in modulating immune and inflammatory responses within the body.47,95–102 Cannabinoids have been shown to both stimulate and attenuate the secretion of various cytokines.103 Most cells within both the innate and adaptive immune system either secrete endocannabinoids, express endocannabinoid receptors, or do both.100 Anti-inflammatory activity appears to be a CBD predominant effect.104 Decreases in several inflammatory markers, including IL-6, TNF-α, COX-2, and iNOS, prostaglandin E2 have been demonstrated in vitro and in vivo.104 CB2 has been shown via in vivo animal models to inhibit Ig-E mediated mast cell activation which would otherwise result in edema and hyperalgesia.105 CB2 has been shown to play a role in allergic inflammatory responses, being expressed by many immunologic cells including eosinophils, neutrophils and mast cells.95,97,98,106 As a modulator of many immune and inflammatory responses, the ESS could potentially be harnessed for use in the management of a variety of disease processes including wound healing, acute and chronic inflammatory disorders, and cancer.103 Olah et al. demonstrated sebostatic and general anti-inflammatory effects of CBD application to skin, making it a potential treatment for acne, other inflammatory skin disorders, and possibly even wound healing.107,108

**Cancer**

Increased cannabinoid receptor expression has been demonstrated in a variety of tumor cell types. Endocannabinoids can be expressed at higher concentrations in cell populations adjacent to premalignant and malignant cells.109 The first study to demonstrate antineoplastic activity of cannabis was completed by Munson in 1975.110 Antineoplastic mechanisms appear to include increased reactive oxygenation species, inhibition of angiogenesis, and arrest of cell-cycle progression, as well as induction of autophagy and apoptosis.111–114 A common basis for antineoplastic activity of cannabinoids appears to be arrest of cell cycle and inhibition of angiogenesis.115

Although presently absent within otolaryngology literature, there is encouraging in vitro and in vivo data demonstrating significant antineoplastic potential of the ESS within a wide variety of cancer models.34,38,109,116 The ENT-related tumors with data demonstrating the potential antineoplastic activity of cannabinoids include

---

**TABLE IV. Summary of Cannabinoid-Based Therapies.**

| Brand Name | Generic Name | Form | Type of Cannabinoid | Indications for Use |
|------------|--------------|------|---------------------|---------------------|
| Marinol    | Dronabinol   | Capsules | Synthetic (Schedule III) | Chemotherapy induced nausea and vomiting, stimulation of appetite |
| Cesamet    | Nabilone     | Capsules | Synthetic (Schedule II) | Chemotherapy induced nausea and vomiting |
| ‘Sativex   | Nabiximols   | Liquid | Cannabis extract (THC & CBD) | MS spasticity, neuropathic pain. Not yet approved for US. |
| ‘Epidiolex | Liquid       | Cannabis extract (98% CBD) | FDA orphan designation for Dravet Syndrome, Lennox-Gastaut Syndrome |

*Not currently FDA approved for use within U.S.A.*
oropharyngeal and tongue cancer, thyroid cancer, lymphoma, basal cell, squamous cell, and melanoma.5,7,27,36,38,68,79,107,117–127 Using a mouse model, Shi et al. demonstrated a strong antitumoral effect on anaplastic thyroid cancer cell lines. In addition to the direct effects observed, ESS agonism was also shown to increase paclitaxel induced apoptosis by two-fold via an unknown synergistic mechanism.7 A summary of data relating to thyroid cancer is shown in Table V.

Unfortunately, our understanding of the antineoplastic mechanisms of cannabinoids is limited. It will be interesting to see if the pro-apoptotic, anti-proliferative, anti-migrative, anti-invasive, anti-metastatic and anti-angiogenic properties of cannabinoids described in preclinical research can be translated into meaningful clinical therapies in the coming years.114 Although the data is primarily in favor of cannabinoids functioning in an antineoplastic manner, there are some reports which suggest that cannabinoids may act as either carcinogenic or antineoplastic depending on the concentration.25,34,128–130

FEDERAL RESTRICTIONS RELATING TO RESEARCH OF CANNABIS AND ITS DERIVATIVES

Current federal regulations relating to research of cannabis and cannabis derivatives are highly restrictive. Currently, research can only be conducted using specific marijuana strains held at the University of Mississippi. In order to conduct marijuana research, one must obtain permission or licensure from three distinct federal entities, as well as obtaining appropriate state permissions.

Laryngoscope Investigative Otolaryngology 3: June 2018 Bryant et al.: Cannabis and ESS Modulators in ENT
Registration is obtained via the Drug Enforcement Agency (DEA), the cannabis plant material to be used for research is obtained through the National Institute on Drug Abuse (NIDA), and finally, an investigational new drug application and research protocol must be approved by the Federal Drug Administration (FDA). Most research that is approved is aimed at exploring negative effects of use, rather than therapeutic research. The current restrictions on research also prevent many modern cannabis strains (which may have varying therapeutic potential) from being studied.131

Interestingly, while the FDA maintains its schedule I classification (no accepted medical use, high potential for abuse), the federal government also holds one of the few patents related to cannabis. In 2003, the Department of Health and Human Services was awarded patent US1999/008769, which describes cannabinoids as having antioxidant and neuroprotective effects making “cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases.”

Although the stance of physicians toward cannabis use is varied, there is a current trend by many physician groups to decriminalize marijuana as schedule I.131,132 Groups such as the American Medical Association, Institute of Medicine, American College of Physicians, and the American Academy of Pediatrics support FDA reclassifying marijuana as a schedule II drug.131 This reclassification would be promoted with the intent to increase research and allow unbiased application of the scientific method toward better understanding the marijuana plant and its potential therapeutic benefits as well as its harmful effects.

CONCLUSIONS

Much is yet to be determined in relation to both adverse and beneficial effects of cannabis use. New data appears to demonstrate many potentially therapeutic possibilities for modulators of the endocannabinoid signaling system. Some of the key areas of interest for the otolaryngologist include its potential effects in cases of oral cancer, thyroid cancer and skin cancer. The most compelling data has currently been achieved via in vitro or in vivo animal studies and has yet to be demonstrated in human clinical trials. Reclassification of marijuana as a schedule II substance would allow for more robust research within the United States while still maintaining a high level of regulatory oversight.

BIBLIOGRAPHY

1. United Nations Office on Drugs and Crime. World drug report. 2010.
2. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011;163:7;1344–1364.
3. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014;370(23):2219–2227.
4. Farrell M, Buchbinder R, Hall W. Should doctors prescribe cannabinoids? BMJ 2014;348:g2737.
5. Blazquez C, Carracedo A, Barrado L, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006;20(14):2633–2635.
6. Galve-Roper I, Sanchez C, Cortes ML, Gomez del Pulgar T, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2006;12(1):313–319.
7. Shi Y, Zou M, Baitiei EV, et al. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene Ther 2008;15(2):101–107.
8. Abrams DI, Guzman M. Cannabis in cancer care. Clin Pharmacol Ther 2015;97(6):575–586.
9. Gaoni D, Mechoulam R. Isolation, structure, and partial synthesis of the active constituent of hashish. J Am Chem Soc 1964;86:1646–1657.
10. Svizrenka I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures—a short review. Pharmacol Biochem Behav 2008;90(4):501–511.
11. Kramer JL. Medical marijuana for cancer. CA Cancer J Clin 2015;65(2):109–122.
12. Costa R, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 2007;566(1–3):175–83.
13. Zuardi AW, Sharrakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology (Berl) 1982;76(1):255–250.
14. Chagas MH, Crippa JA, Zuardi AW, et al. Effects of acute systemic administration of cannabinoid on sleep-wake cycle in rats. J Psychopharmacol 2012;27(3):312–316.
15. Abrams DI, Yzzooz HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: A pilot study. Clin Pharmacol Ther 2007;82(5):572–578.
16. Hiller PC, Wilson FJ, Jr, Mazumder MK, Wilson JD, Bone RC. Concentration and particle size distribution in smoke from marijuana cigarettes with different delta-9-tetrahydrocannabinol content. Fundam Appl Toxicol 1984;4:3 Pt 1:451–454.
17. Matthias P, Tashkin DP, Marques-Magalhaes JA, Wilkins JN, Simmons MS. Effects of varying marijuana potency on deposition of tar and delta-9-THC in the lung during smoking. Pharmacol Biochem Behav 1997;58(4):1145–1150.
18. Muir D, Eickert WS, Levassor G, et al. Comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol 2008;21(2):494–502.
19. Owen KP, Sutter ME, Albertson TE. Marijuana: respiratory tract effects. Clin Rev Allergy Immunol 2013;45(3):199–210.
20. Solowij N, Broyd SJ, van Heil HH, Hazekamp A. A protocol for the delivery of cannabinoids (CBD) and combined CBD and 9-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacol Toxicol 2014;15:58–6511–15–58.
21. Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F. The medicinal use of cannabis and cannabinoids—an international cross-sectional survey on administration forms. J Psychoactive Drugs 2013;45(3):199–210.
22. Zuurlman L, Roy C, Schoemaker BC, et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol 2008;22(7):707–716.
23. Hajek P, Ettor J, Benowitz N, Eisenberg T, McRobbie H. Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction 2014;109:11:1801–1810.
24. Shihab M, Villarreal A, Bouhoul K, Lin S, Talboys P, Metcalfe and silicate particles including nanoparticles are present in electronic cigarette cartridge fluid and aerosol. PLoS One 2013;8(3):e57897. doi: 10.1371/journal.pone.0057897 [pii].
25. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008;7:415–458.
26. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258(5090):1468–1469.
27. Adinolfi B, Romani R, Anni, and Vanni A, et al. Anticancer activity of anandamide in human cutaneous melanoma cells. Eur J Pharmacol 2013;718:1–3;154–159.
28. Chicca A, Marazzi J, Nicelli S, Gertsch J. Evidence for bidirectional endocannabinoid transport across cell membranes. J Biol Chem 2012;287(41):34660–34662.
29. Fowler CJ. Anandamide uptake explained? Trends Pharmacol Sci 2012;33(4):181–185.
30. Turu G, Varnai P, Gombolai P, et al. Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other gp11 protein-coupled receptors. J Biol Chem 2009;284(25):16914–16921.
31. Gombolai P, Pap D, Turu G, Czil K, Bagdy G, Hanuszay L. Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action. Mol Cell Endocrinol 2012;353(1–2):29–36.
32. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TJ. Structure of the peripheral receptor for cannabinoids. Nature 1993;365(6441):561–564.
33. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365(6441):61–65.
34. Alexander A, Smith PF, Rosengren RJ. Cannabinoids in the treatment of cancer. Curr Opin Pharmacol 2009;8(5):14–16.
35. Wilson BJ, Nicoll BA. Endocannabinoid signaling in the brain. Science 2002;296:556–8. 
36. Gustafsson K, Wang X, Severa D, et al. Expression of cannabinoid receptors type 1 and 2 in non-hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer 2008;123(5):1025–1033. 
37. Medizinal VE, Adler-Graschinsky E. Cannabinoid system as a potential target for new drug development in the treatment of cardiovascular disease. Curr Pharm Des 2003;9(14):391–11. 
38. Whyte DA, Al-Hammadi S, Balhaj G, Brown OM, Penefsky HS, Souid AK. Cannabinoids inhibit cellular respiration of human oral cancer cells. Pharmacology 2005;78(5–6):288–335. 
39. Begg M, Pacher P, Batki S, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005;106(2):135–145. 
40. Pertew BG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabinvarin. Br J Pharmacol 2008;153(2):199–215. 
41. Gonzalez Del Paluzar T, De Ceballos ML, Guzman M, Velasco G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 2002;277(39):36527–36533. 
42. Bousabala M, Poinot-Chazel C, Bourrie B, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995;312(2):367–364. 
43. Hudson, BD, Hebert TE, Kelly ME. Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol Pharmacol 2010;77(1):1–9. 
44. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011;50(2):193–211. 
45. Bifulco M, Malitante AM, Pisanti S, Laezza C. Endocannabinoids in endo- and peripheral targets: new therapeutic perspectives. J Pain 2008;9(15):391–408. 
46. Bousabala M, Poinot-Chazel C, Marchand J, et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor, involvement of both mitogen-activated protein kinase and induction of NF-kB expression. Br J Pharmacol 1996;118(3):704–711. 
47. Han KH, Lim S, Ryu J, et al. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardioscience 2008;43(6):566–570. 
48. Nelson B. Cannabis conundrum: evidence of harm? Opposition to mari- juana use is rooted in arguments about the drug’s harm to children and adults, but the scientific evidence is seldom clear-cut. Cancer Cytopathol 2015;123(1):1–2. 
49. Van Houzen B, Cross C. Respiratory tract effects of marijuana. Clin Rev Allergy Immunol 2005;29(3):243–269. 
50. Mokra Y, Cagie S, Landy B, Manaf O, Roiser J, Curran H. Neuropsychological and educational outcomes related to adolescent cannabis use, a prospective cohort study. Eur Neuropsychopharmacol 2014;24(2):5965. 
51. Meier MH, Cami A, Ambler A, et al. Persistent cannabis users show neu- ropyschological decline from childhood to midlife. Proc Natl Acad Sci U S A 2012;109(4):E2657–E2664. 
52. Riegger O. Correlations between cannabis use and IQ change in the dun- edlin cohort are consistent with confounding from socioeconomic status. Proc Natl Acad Sci U S A 2013;110(11):4251–4254. 
53. Sewell RA, Poling J, Sehuguglu M. The effect of cannabis compared with alcohol on driving. Am J Addict 2009;18(3):185–193. 
54. Hartung B, Rehn U. Cannabis. Effects on driving. Clin Chem 2013;59(5):747–56. 
55. Gerberth SG, Sieden S, Braun LB, Tokawa IS, Tolan KK, Quesenberry CP. Marijuana use and injury events resulting in hospitalization. Ann Epidemiol 2003;13(4):230–237. 
56. Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 2015;110:119–135. 
57. Hayakawak MR, Flannery VJ, Gibbons KS, et al. Birth outcomes associ- ated with cannabis use before and during pregnancy. Pediatr Neurol 2011;71(2):215–219. 
58. Hartung B, Kaufeinstein S, Zitz-Timme S, Daldup T. Sudden unexpected death under acute influence of cannabis. Forensic Sci Int 2014;237(1):e1–13. 
59. Mateu I, Pineda A, Gomez-Beldarrain JM, Barretrexa JM, Garcia-Monco JC. Recurrent stroke associated with cannabis use. J Neurol Neurosurg Psychiatry 2005;76(3):435–437. 
60. Zhang LR, Morgenstern H, Greenland S, et al. Cannabis smoking and lung cancer risk: pooled analysis in the international lung cancer con- sortium. Int J Cancer 2015;136:8493–903. 
61. Berthiller J, Straif K, Boniol M, et al. Sudden unexpected death produced by marijuana smoke. an adverse effect enhanced by can- nabinoids. Respir Crit Care Med 2008;296(5568):678–682. 
62. Hashibe M, Straif K, Tashkin D, et al. Endocannabinoid signaling in the brain. Science 2002;296:556–8. 
63. Gustafsson K, Wang X, Severa D, et al. Expression of cannabinoid receptors type 1 and 2 in non-hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer 2008;123(5):1025–1033. 
64. Whyte DA, Al-Hammadi S, Balhaj G, Brown OM, Penefsky HS, Souid AK. Cannabinoids inhibit cellular respiration of human oral cancer cells. Pharmacology 2005;78(5–6):288–335. 
65. Aldington S, Harwood M, Cox B, et al. Marijuana use and cancer of the head and neck: Case-control study. Otolaryngol Head Neck Surg 2008;138(3):374–389. 
66. Hashibe M, Straif K, Tashkin D, et al. Endocannabinoid signaling in the brain. Science 2002;296:556–8.
95. Karsak M, Gaffal E, Date R, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. *Science* 2007;316(5830):1494–1497.

96. Klein TW, Newton C, Larsen K, et al. Cannabinoid receptors and T helper cells. *J Neuroimmunol* 2004;147(1–2):91–94.

97. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nat Rev Immunol* 2005;5(5):400–411.

98. Bouaboula M, Rinaldi M, Carayon P, et al. Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem* 1993;214(1):173–180.

99. Cabreral GA, Dove Pettit DA. Drugs and immunity: Cannabinoids and their role in decreased resistance to infectious disease. *J Neuroimmunol* 1988;83(1–2):116–123.

100. Chiurchiu V, Battistini L, Maccarrone M. Endocannabinoid signaling in innate and adaptive immunity. *Immunology*. 2015;144(3):352–364.

101. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem* 1995;229(1):54–61.

102. Witkamp R, Mejerink J. The endocannabinoid system: An emerging key player in inflammation. *Curr Opin Clin Nutr Metab Care* 2014;17(2):130–138.

103. Croxford JL, Yamamura T. Cannabinoids and the immune system: Potentiation of the skin in health and disease: Novel perspectives and therapeutic opportunities. *Trends Pharmacol Sci* 2009;30(8):411–420.

104. Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. *Bioorg Med Chem* 2015;23(7):1377–1385.

105. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N2-hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. *Eur J Pharmacol* 1996;306(3):227–236.

106. Kishimoto S, Oka S, Gokoh M, Sugiyama T. Chemotaxis of human peripheral blood eosinophils to 2-arachidonoylglycerol: Comparison with other eosinophil chemotactants. *Int Arch Allergy Immunol* 2006;140(Suppl 1):3–7.

107. Biro T, Toth BI, Haasko G, Paus R, Pacher P. The endocannabinoid system of the skin in the health and disease: Novel perspectives and therapeutic opportunities. *Trends Pharmacol Sci* 2009;30(8):411–420.

108. Yang J, Zhao H, Fang X, Li H. Cannabinoid receptor 2 is upregulated in melanoma. *J Cancer Res Ther* 2012;8(4):549–554.

109. Zhao ZG, Li YY, Yang J, Li HJ. Zhao H. Expression of cannabinoid receptor 2 in squamous cell carcinoma. *Nat Fang Yi Ke Da Xue Xue Bao* 2010;30(3):593–595.

110. Bostwick JM. Blurred boundaries: The therapeutics and politics of medical marijuana. *Mayo Clin Proc* 2012;87(2):172–186. Accessed 17 October 2014.

111. Hoffmann DE, Weber E. Medical marijuana and the law. *N Engl J Med* 2010;362(16):1453–1457.

112. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via a tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. *Cancer Res* 2004;64(6):1943–1950.

113. Sanchez MG, Ruiz-Llorente L, Sanchez AM, Diaz-Laviada I. Activation of cannabinoid receptors expressed in prostate PC-3 cells. Involvement in raf-1 phosphoinositide 3-kinase/PKB pathway by CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. *Adv Exp Med Biol* 1999;469:527–533.

114. Szabo CG, Szabo Z, Szabo E, et al. Endocannabinoids are required for ultraviolet-induced inflammation and skin cancer development. *Cancer Res* 2008;68(10):3992–3998.

115. Hoffmann DE, Weber E. Medical marijuana and the law. *N Engl J Med* 2010;362(16):1453–1457.